Nuo Therapeutics (AURX) more than doubles sales but stays in loss

Rhea-AI Filing Summary

Nuo Therapeutics, Inc. reported sharply higher revenue for the quarter ended June 30, 2026 and a smaller loss while updating on key commercial and financing developments. For the second quarter, total revenue was $1,768,986, up from $700,202 a year earlier, driven mainly by product sales growth. Gross profit increased to $1,170,027, and the quarterly net loss narrowed to $277,601 from $649,689, with loss per share steady at $0.01.

For the first half of 2026, revenue rose to $3,071,101 from $1,184,583, while the net loss improved to $896,067 from $1,395,817. The balance sheet shows total assets of $2,626,290 and total liabilities of $4,161,604, resulting in a stockholders’ deficit of $1,535,314. Management highlighted continued positive performance of the Smith+Nephew private label arrangement, confirmation of a reimbursement fee milestone expected to be paid this quarter, and an amended loan agreement providing additional working capital with an option to increase total borrowings on September 30, 2026 as the company works toward breakeven operations.

Positive

• Quarterly revenue more than doubled to $1,768,986 from $700,202 year over year, with gross profit rising to $1,170,027 and net loss narrowing to $277,601, indicating significantly improved operating performance.
• First-half revenue climbed to $3,071,101 from $1,184,583 and net loss improved to $896,067 from $1,395,817, while management reported a positively performing Smith+Nephew distribution arrangement and an expected reimbursement milestone payment this quarter.

Negative

• Stockholders’ deficit widened to $1,535,314 with total liabilities of $4,161,604 exceeding total assets of $2,626,290, reflecting a leveraged and negative equity position.
• Interest expense increased materially, contributing to net other expense of $111,049 for the quarter and $283,049 for the first half of 2026, and notes payable rose to $1,436,250 plus a $314,000 related-party note.

Filing Explained

The reported share base rose to 48.4 million by June 30, while the filing does not establish the terms or cause of that increase.

This Form 8-K reports the second-quarter results under Item 2.02 and furnishes the accompanying press release as Exhibit 99; the financial information is therefore disclosed in this filing rather than presented as a new completed financing.

At June 30, 2026, the company reported 48,418,524 issued and outstanding common shares, compared with 48,179,039 at December 31, 2025. The filing does not identify what caused that increase or provide related issuance terms.

Additional shares increase the total share count and can reduce an existing holder’s percentage ownership absent offsetting changes. The balance sheet separately records $1,436,250 of notes payable and $314,000 owed under a related-party note, while the company describes a separate option to increase borrowings; recorded debt is an obligation, whereas the option is only borrowing capacity.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q2 2026 Total Revenue: $1,768,986 Q2 2026 Net Loss: $277,601 First-Half 2026 Revenue: $3,071,101 +5 more

8 metrics

Q2 2026 Total Revenue $1,768,986 Three months ended June 30, 2026, compared with $700,202 in Q2 2025

Q2 2026 Net Loss $277,601 Three months ended June 30, 2026, compared with $649,689 in Q2 2025

First-Half 2026 Revenue $3,071,101 Six months ended June 30, 2026, compared with $1,184,583 in 2025

First-Half 2026 Net Loss $896,067 Six months ended June 30, 2026, compared with $1,395,817 in 2025

Total Assets $2,626,290 Balance sheet as of June 30, 2026

Total Liabilities $4,161,604 Balance sheet as of June 30, 2026

Stockholders’ Deficit $1,535,314 Balance sheet as of June 30, 2026

Notes Payable $1,436,250 Non-current notes payable as of June 30, 2026

Key Terms

distribution fee revenue, deferred revenue, stockholders' deficit, autologous, +1 more

5 terms

distribution fee revenue financial

"Distribution fee revenue | $ | 77,941"

deferred revenue financial

"Deferred revenue | 311,765 | Deferred revenue – long term | 857,353"

Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.

stockholders' deficit financial

"Total stockholders' deficit | (1,535,314 )"

When a company's total liabilities exceed its total assets, the owner's equity becomes negative and is reported as a stockholders' deficit. It shows that, on paper, the business owes more than it owns — like a homeowner whose mortgage balance is larger than the home's market value. Investors watch this because it signals financial strain, higher risk of dilution or default, and can limit a company's ability to pay dividends, borrow, or grow.

autologous medical

"another differentiated autologous therapy and are pleased to report"

Autologous describes a medical product or treatment made from a patient’s own cells or tissues rather than from a donor. For investors, autologous approaches matter because they can lower the risk of immune rejection and improve effectiveness, but they often require individualized manufacturing, complex logistics, and higher per-patient costs—factors that affect scalability, pricing, and regulatory hurdles in healthcare businesses.

forward-looking statements regulatory

"Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Earnings Snapshot

Q2 2026 Total Revenue: $1,768,986

Quarter and six months ended June 30, 2026

Q2 2026 Total Revenue $1,768,986 Increased from $700,202 in Q2 2025

Q2 2026 Net Loss $277,601 Improved from net loss of $649,689 in Q2 2025

First-Half 2026 Revenue $3,071,101 Increased from $1,184,583 in the first half of 2025

First-Half 2026 Net Loss $896,067 Improved from net loss of $1,395,817 in the first half of 2025

FAQ

How did Nuo Therapeutics (AURX) perform financially in the second quarter of 2026?

Nuo Therapeutics reported Q2 2026 revenue of $1,768,986 and a net loss of $277,601. Revenue increased significantly from $700,202 in Q2 2025, while the net loss narrowed from $649,689, with basic and diluted loss per share steady at $0.01.

What were Nuo Therapeutics’ first-half 2026 results compared with 2025?

For the six months ended June 30, 2026, Nuo generated revenue of $3,071,101 and a net loss of $896,067. This compares with revenue of $1,184,583 and a net loss of $1,395,817 for the same period in 2025, reflecting higher sales and a reduced loss.

What does Nuo Therapeutics’ balance sheet look like as of June 30, 2026?

As of June 30, 2026, Nuo reported total assets of $2,626,290 and total liabilities of $4,161,604. The company had a stockholders’ deficit of $1,535,314, including notes payable of $1,436,250 and a related-party note payable of $314,000.

How is the Smith+Nephew arrangement impacting Nuo Therapeutics (AURX)?

Management stated that the Smith+Nephew private label arrangement for Nuo’s autologous therapy “continues to perform positively”. Nuo also confirmed achievement of a reimbursement fee milestone in last year’s distribution agreement and anticipates receiving the related payment during the current quarter.

What financing developments did Nuo Therapeutics report related to its loan agreement?

Nuo reported that it amended a January loan agreement in May, adding capital via interim funding. The company also has an option to increase total borrowings under this agreement on September 30, 2026, with the loan intended to provide working capital as it pursues breakeven operations.

Is Nuo Therapeutics (AURX) currently profitable based on these results?

No. Nuo reported a Q2 2026 net loss of $277,601 and a first-half 2026 net loss of $896,067. While losses narrowed compared with 2025, the company continues to operate at a loss and is using loan financing to support working capital.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/17/2026 - 07:55 AM Accepted by SEC EDGAR 08/17/2026 - 07:55 AM Learn about SEC filing dates

false 0001091596 0001091596 2026-08-17 2026-08-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 17, 2026

Nuo Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

Delaware	000-28443	23-3011702
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

8285 El Rio, Suite 190, Houston, Texas 77054

(Address of principal executive offices) (Zip Code)

(346) 396-4770

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:  None

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02 Results of Operations and Financial Condition

On August 17, 2026, Nuo Therapeutics, Inc. (“Nuo”) issued a press release announcing its financial results for the second quarter of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference.

The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99		Press Release of Nuo Therapeutics, Inc. dated August 17, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Nuo Therapeutics, Inc.
	By:	/s/ David E. Jorden
		David E. Jorden
		Chief Executive and Chief Financial Officer

Date: August 17, 2026

Exhibit 99

8285 El Rio, Suite 190 Houston, TX 77054 Phone 833.298.6633

NUO THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Differentiated Autologous PRP Remains Well-Positioned for Attractive Long-Term Growth

Houston, TX – August 17, 2026 – Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the second quarter ended June 30, 2026 and provided an operational and business update.

Second Quarter and First Half 2026 Financial Summary

● Total revenues of approximately $1.77 million and $3.07 million for the second quarter 2026 and first half of 2026, respectively, were each up in excess of 150% versus the comparable 2025 periods

● Total 2Q product revenues increased 38% sequentially versus 1Q 2026 with Aurix branded product revenues increasing in excess of 30% sequentially

● Second quarter net operating loss of approximately $167,000 improved by approximately $280,000 compared to the first quarter of 2026

● Amended and restated loan and agreement with an interim funding of $675,000 and with $325,000 remaining available under commitments totaling $2 million

Operational and Business Update

● Market continues to respond positively to absolute and relative improvement in Medicare related reimbursement for Aurix and a vastly changed overall reimbursement landscape

● Proposed Medicare PFS and OPPS reimbursement rules issued in July for January 1, 2027 effectiveness, if finalized as proposed, would support stable or increasing Medicare payment amounts for autologous PRP therapies

“Market dynamics continue to support attractive growth opportunities for the Aurix brand and, by extension, Smith+Nephew’s private label offering. We remain two months shy of the one-year anniversary of Smith+Nephew’s market entry and the initial availability of their private label brand as another differentiated autologous therapy and are pleased to report that the arrangement continues to perform positively”, commented David Jorden, Nuo’s Chief Executive and Financial Officer. “We recently confirmed the achievement of a reimbursement fee milestone contained in last year’s distribution agreement and anticipate receiving that payment this quarter”.

“We amended January’s loan agreement in May with additional capital made available via an interim funding and have the company option to increase total borrowings under the agreement on September 30, 2026. The loan remains designed to provide working capital as we invest in growth and move closer to breakeven operations”.

About Nuo Therapeutics

Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Nuo’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements include but are not limited to statements regarding Nuo’s anticipated growth opportunities and market positioning, expectations regarding the impact of Medicare reimbursement changes and their impact on demand for Aurix products, future receipt of milestone payments, and movement toward breakeven operations. Forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” and “should,” “could,” “potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under "Risk Factors" and elsewhere in Nuo’s public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

Contact:

David Jorden

djorden@nuot.com

NUO THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

​	​	June 30, 2026		​	​	December 31, 2025		​
ASSETS	​	​	​	​	​	​	​	​
Current assets	​	​	​	​	​	​	​	​
Cash	​	$	449,325	​	​	$	548,946	​
Accounts receivable, net	​	​	1,167,571	​	​	​	561,667	​
Inventory, net	​	​	269,518	​	​	​	213,761	​
Prepaid expenses and other current assets	​	​	107,021	​	​	​	55,509	​
Total current assets	​	​	1,993,435	​	​	​	1,379,883	​
​	​	​	​	​	​	​	​	​
Property and equipment, net	​	​	571,735	​	​	​	366,315	​
Operating lease right of use assets	​	​	61,120	​	​	​	99,464	​
Total assets	​	$	2,626,290	​	​	$	1,845,662	​
​	​	​	​	​	​	​	​	​
LIABILITIES AND STOCKHOLDERS' DEFICIT	​	​	​	​	​	​	​	​
Current liabilities	​	​	​	​	​	​	​	​
Accounts payable	​	$	563,100	​	​	$	436,083	​
Accrued expenses	​	​	619,046	​	​	​	493,792	​
Deferred revenue	​	​	311,765	​	​	​	300,000	​
Current portion of operating lease liabilities	​	​	60,090	​	​	​	76,410	​
Total current liabilities	​	​	1,554,001	​	​	​	1,306,285	​
​	​	​	​	​	​	​	​	​
Deferred revenue – long term	​	​	857,353	​	​	​	975,000	​
Notes payable	​	​	1,436,250	​	​	​	300,000	​
Note payable – related party	​	​	314,000	​	​	​	200,000	​
Non-current portion of operating lease liabilities	​	​	-	​	​	​	20,936	​
Total liabilities	​	​	4,161,604	​	​	​	2,802,221	​
​	​	​	​	​	​	​	​	​
Commitments and contingencies	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​
Stockholders' deficit	​	​	​	​	​	​	​	​
Common stock; $0.0001 par value, 100,000,000 shares authorized, 48,418,524 and 48,179,039 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	​	​	4,842	​	​	​	4,818	​
Additional paid-in capital	​	​	34,128,073	​	​	​	33,810,785	​
Accumulated deficit	​	​	(35,668,229	)	​	​	(34,772,162	)
Total stockholders' deficit	​	​	(1,535,314	)	​	​	(956,559	)
​	​	​	​	​	​	​	​	​
Total liabilities and stockholders' deficit	​	$	2,626,290	​	​	$	1,845,662	​

NUO THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

​	​	Three  Months ended June 30, 2026		​	​	Three  Months ended June 30, 2025		​
Revenue	​	​	​	​	​	​	​	​
Product sales	​	$	1,691,045	​	​	$	625,202	​
Distribution fee revenue	​	​	77,941	​	​	​	75,000	​
Total revenue	​	​	1,768,986	​	​	​	700,202	​
​	​	​	​	​	​	​	​	​
Costs of sales	​	​	598,959	​	​	​	159,350	​
Gross profit	​	​	1,170,027	​	​	​	540,852	​
​	​	​	​	​	​	​	​	​
Operating expenses	​	​	​	​	​	​	​	​
Selling, general and administrative	​	​	1,336,579	​	​	​	1,192,874	​
Total operating expenses	​	​	1,336,579	​	​	​	1,192,874	​
​	​	​	​	​	​	​	​	​
Loss from operations	​	​	(166,552	)	​	​	(652,022	)
​	​	​	​	​	​	​	​	​
Other income (expense)	​	​	​	​	​	​	​	​
Interest income (expense), net	​	​	(114,066	)	​	​	1,153	​
Other income	​	​	3,017	​	​	​	1,180	​
Total other income (expenses)	​	​	(111,049	)	​	​	2,333	​
​	​	​	​	​	​	​	​	​
Net loss	​	$	(277,601	)	​	$	(649,689	)
​	​	​	​	​	​	​	​	​
Loss per common share				​	​	​	​	​
Basic and diluted	​	$	(0.01	)	​	$	(0.01	)
​	​	​	​	​	​	​	​	​
Weighted average common shares outstanding				​	​	​	​	​
Basic and diluted	​	​	48,407,917	​	​	​	46,823,111	​

NUO THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

​	​	Six Months ended June 30, 2026		​	​	Six Months ended June 30, 2025		​
Revenue	​	​	​	​	​	​	​	​
Product sales	​	$	2,915,219	​	​	$	1,109,583	​
Distribution fee revenue	​	​	155,882	​	​	​	75,000	​
Total revenue	​	​	3,071,101	​	​	​	1,184,583	​
​	​	​	​	​	​	​	​	​
Costs of sales	​	​	1,051,347	​	​	​	280,371	​
Gross profit	​	​	2,019,754	​	​	​	904,212	​
​	​	​	​	​	​	​	​	​
Operating expenses	​	​	​	​	​	​	​	​
Selling, general and administrative	​	​	2,632,772	​	​	​	2,301,381	​
Total operating expenses	​	​	2,632,772	​	​	​	2,301,381	​
​	​	​	​	​	​	​	​	​
Loss from operations	​	​	(613,018	)	​	​	(1,397,169	)
​	​	​	​	​	​	​	​	​
Other income (expense)	​	​	​	​	​	​	​	​
Interest income (expense), net	​	​	(289,348	)	​	​	(442	)
Other income	​	​	6,299	​	​	​	1,794	​
Total other income (expenses)	​	​	(283,049	)	​	​	1,352	​
​	​	​	​	​	​	​	​	​
Net loss	​	$	(896,067	)	​	$	(1,395,817	)
​	​	​	​	​	​	​	​	​
Loss per common share				​	​	​	​	​
Basic and diluted	​	$	(0.02	)	​	$	(0.03	)
​	​	​	​	​	​	​	​	​
Weighted average common shares outstanding				​	​	​	​	​
Basic and diluted	​	​	48,346,949	​	​	​	46,819,632	​

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99 EXHIBIT 99 177.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 10.5 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 14.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.5 KB